DDInter1174 DDInter1435
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Methotrexate {u} (Compound) resembles {v} (Compound) Raltitrexed
Methotrexate {u} (Compound) resembles {v} (Compound) Tetrahydrofolic acid
Methotrexate {u} (Compound) treats {v} (Disease) stomach cancer
Methotrexate {u} (Compound) binds {v} (Gene) SLC16A1
Methotrexate {u} (Compound) upregulates {v} (Gene) PDLIM1
Methotrexate {u} (Compound) is included by {v} (Pharmacologic Class) Folic Acid Metabolism Inhibitors
Methotrexate {u} (Compound) downregulates {v} (Gene) TMEM50A
Methotrexate {u} (Compound) causes {v} (Side Effect) Ecchymosis
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tromethamine
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Haloperidol
Methotrexate (Compound) resembles Raltitrexed (Compound)
Methotrexate (Compound) resembles Tetrahydrofolic acid (Compound)
Methotrexate (Compound) treats stomach cancer (Disease)
Methotrexate (Compound) binds SLC16A1 (Gene)
Methotrexate (Compound) upregulates PDLIM1 (Gene)
Methotrexate (Compound) is included by Folic Acid Metabolism Inhibitors (Pharmacologic Class)
Methotrexate (Compound) downregulates TMEM50A (Gene)
Methotrexate (Compound) causes Ecchymosis (Side Effect)
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Haloperidol